Lifecore Biomedical, Inc. (LFCR)
USD 5.81
(1.57%)
USD 5.81
(1.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 49.03 Million USD | -4.33% |
| 2023 | 51.25 Million USD | 1.56% |
| 2022 | 50.47 Million USD | -33.23% |
| 2021 | 75.58 Million USD | -9.25% |
| 2020 | 83.28 Million USD | 10.27% |
| 2019 | 75.52 Million USD | 16.64% |
| 2018 | 64.75 Million USD | -4.33% |
| 2017 | 67.68 Million USD | 19.28% |
| 2016 | 56.74 Million USD | 20.87% |
| 2015 | 46.94 Million USD | 10.79% |
| 2014 | 42.37 Million USD | 11.83% |
| 2013 | 37.89 Million USD | 4.85% |
| 2012 | 36.14 Million USD | 6.66% |
| 2011 | 33.88 Million USD | 53.6% |
| 2010 | 22.05 Million USD | 1.74% |
| 2009 | 21.68 Million USD | -5.94% |
| 2008 | 23.05 Million USD | 1040.62% |
| 2007 | 2.02 Million USD | -93.49% |
| 2006 | 31.02 Million USD | 19.52% |
| 2005 | 25.95 Million USD | 0.85% |
| 2004 | 25.73 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 30.08 Million USD | -0.51% |
| 2001 | 30.23 Million USD | -23.73% |
| 2000 | 39.64 Million USD | 106.46% |
| 1999 | 19.2 Million USD | 3.23% |
| 1998 | 18.6 Million USD | 38.81% |
| 1997 | 13.4 Million USD | 76.32% |
| 1996 | 7.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.28 Million USD | -0.61% |
| 2024 Q1 | 11.35 Million USD | -17.75% |
| 2024 Q3 | 12.01 Million USD | 6.51% |
| 2024 FY | 49.03 Million USD | -4.33% |
| 2024 Q4 | 14.38 Million USD | 19.7% |
| 2023 Q1 | 12.7 Million USD | -27.29% |
| 2023 Q2 | 12.89 Million USD | 1.43% |
| 2023 Q4 | 13.8 Million USD | 6.69% |
| 2023 FY | 51.25 Million USD | 1.56% |
| 2023 Q3 | 12.93 Million USD | 0.35% |
| 2022 Q3 | 11.78 Million USD | -28.83% |
| 2022 Q1 | 18.76 Million USD | 0.27% |
| 2022 Q2 | 16.55 Million USD | -11.79% |
| 2022 Q4 | 17.47 Million USD | 48.37% |
| 2022 FY | 50.47 Million USD | -33.23% |
| 2021 Q4 | 18.71 Million USD | 5.25% |
| 2021 FY | 75.58 Million USD | -9.25% |
| 2021 Q3 | 17.78 Million USD | -4.8% |
| 2021 Q1 | 20.41 Million USD | -2.33% |
| 2021 Q2 | 18.67 Million USD | -8.49% |
| 2020 Q1 | 19.71 Million USD | -16.92% |
| 2020 FY | 83.28 Million USD | 10.27% |
| 2020 Q2 | 21.55 Million USD | 9.3% |
| 2020 Q3 | 21.53 Million USD | -0.09% |
| 2020 Q4 | 20.89 Million USD | -2.94% |
| 2019 Q3 | 18.58 Million USD | 13.37% |
| 2019 FY | 75.52 Million USD | 16.64% |
| 2019 Q4 | 23.73 Million USD | 27.7% |
| 2019 Q1 | 16.78 Million USD | 0.29% |
| 2019 Q2 | 16.39 Million USD | -2.34% |
| 2018 Q4 | 16.73 Million USD | -1.09% |
| 2018 Q3 | 16.92 Million USD | 3.77% |
| 2018 Q2 | 16.3 Million USD | -2.73% |
| 2018 Q1 | 16.76 Million USD | -2.62% |
| 2018 FY | 64.75 Million USD | -4.33% |
| 2017 Q1 | 15.67 Million USD | -0.11% |
| 2017 FY | 67.68 Million USD | 19.28% |
| 2017 Q4 | 17.21 Million USD | 1.13% |
| 2017 Q3 | 17.02 Million USD | 8.5% |
| 2017 Q2 | 15.68 Million USD | 0.1% |
| 2016 FY | 56.74 Million USD | 20.87% |
| 2016 Q3 | 12.55 Million USD | -13.17% |
| 2016 Q4 | 15.69 Million USD | 24.99% |
| 2016 Q1 | 14.04 Million USD | 12.64% |
| 2016 Q2 | 14.45 Million USD | 2.98% |
| 2015 Q3 | 12.05 Million USD | 2.37% |
| 2015 Q4 | 12.46 Million USD | 3.42% |
| 2015 FY | 46.94 Million USD | 10.79% |
| 2015 Q2 | 11.77 Million USD | 10.51% |
| 2015 Q1 | 10.65 Million USD | -1.69% |
| 2014 Q4 | 10.83 Million USD | 3.97% |
| 2014 Q2 | 10.55 Million USD | 0.02% |
| 2014 Q1 | 10.55 Million USD | 18.38% |
| 2014 FY | 42.37 Million USD | 11.83% |
| 2014 Q3 | 10.42 Million USD | -1.28% |
| 2013 Q3 | 10.84 Million USD | -3.98% |
| 2013 Q1 | 10.76 Million USD | 9.51% |
| 2013 Q4 | 8.91 Million USD | -17.81% |
| 2013 Q2 | 11.29 Million USD | 5.01% |
| 2013 FY | 37.89 Million USD | 4.85% |
| 2012 Q2 | 8.8 Million USD | 5.06% |
| 2012 Q4 | 9.82 Million USD | 7.54% |
| 2012 FY | 36.14 Million USD | 6.66% |
| 2012 Q1 | 8.37 Million USD | -38.93% |
| 2012 Q3 | 9.13 Million USD | 3.82% |
| 2011 FY | 33.88 Million USD | 53.6% |
| 2011 Q2 | 8.32 Million USD | 5.62% |
| 2011 Q3 | 8.73 Million USD | 4.88% |
| 2011 Q4 | 13.71 Million USD | 57.08% |
| 2011 Q1 | 7.88 Million USD | 30.51% |
| 2010 FY | 22.05 Million USD | 1.74% |
| 2010 Q3 | 5.38 Million USD | 5.09% |
| 2010 Q1 | 5.5 Million USD | -4.31% |
| 2010 Q2 | 5.12 Million USD | -6.99% |
| 2010 Q4 | 6.04 Million USD | 12.18% |
| 2009 Q2 | 5.31 Million USD | -4.46% |
| 2009 FY | 21.68 Million USD | -5.94% |
| 2009 Q4 | 5.75 Million USD | 14.14% |
| 2009 Q1 | 5.56 Million USD | -20.89% |
| 2009 Q3 | 5.04 Million USD | -5.12% |
| 2008 Q2 | 5.02 Million USD | -6.35% |
| 2008 FY | 23.05 Million USD | 1040.62% |
| 2008 Q4 | 7.03 Million USD | 25.03% |
| 2008 Q3 | 5.62 Million USD | 11.9% |
| 2008 Q1 | 5.36 Million USD | -0.48% |
| 2007 FY | 2.02 Million USD | -93.49% |
| 2007 Q4 | 5.39 Million USD | 131.38% |
| 2007 Q3 | -17.18 Million USD | -311.44% |
| 2007 Q2 | 8.12 Million USD | 42.97% |
| 2007 Q1 | 5.68 Million USD | -30.75% |
| 2006 Q1 | 6.94 Million USD | 10.49% |
| 2006 FY | 31.02 Million USD | 19.52% |
| 2006 Q2 | 7.97 Million USD | 14.88% |
| 2006 Q3 | 7.89 Million USD | -0.98% |
| 2006 Q4 | 8.21 Million USD | 3.99% |
| 2005 Q3 | 6.86 Million USD | 3.5% |
| 2005 FY | 25.95 Million USD | 0.85% |
| 2005 Q4 | 6.28 Million USD | -8.47% |
| 2005 Q2 | 6.63 Million USD | 7.32% |
| 2005 Q1 | 6.17 Million USD | -6.41% |
| 2004 Q1 | 6.4 Million USD | -18.44% |
| 2004 Q3 | 6.51 Million USD | 4.73% |
| 2004 Q4 | 6.6 Million USD | 1.38% |
| 2004 FY | 25.73 Million USD | 0.0% |
| 2004 Q2 | 6.21 Million USD | -2.9% |
| 2003 Q2 | 7.29 Million USD | 2.33% |
| 2003 Q3 | 7.59 Million USD | 4.1% |
| 2003 FY | - USD | -100.0% |
| 2003 Q4 | 7.85 Million USD | 3.4% |
| 2003 Q1 | 7.12 Million USD | -11.36% |
| 2002 Q4 | 8.04 Million USD | 5.62% |
| 2002 Q1 | 7.91 Million USD | -5.72% |
| 2002 Q2 | 4.65 Million USD | -41.14% |
| 2002 Q3 | 7.61 Million USD | 63.52% |
| 2002 FY | 30.08 Million USD | -0.51% |
| 2001 Q4 | 8.39 Million USD | -9.52% |
| 2001 Q3 | 9.27 Million USD | -13.28% |
| 2001 Q2 | 10.69 Million USD | 4.8% |
| 2001 Q1 | 10.2 Million USD | -4.95% |
| 2001 FY | 30.23 Million USD | -23.73% |
| 2000 FY | 39.64 Million USD | 106.46% |
| 2000 Q2 | 4.9 Million USD | 6.52% |
| 2000 Q4 | 10.73 Million USD | 32.56% |
| 2000 Q3 | 8.1 Million USD | 65.31% |
| 2000 Q1 | 4.6 Million USD | -13.21% |
| 1999 Q1 | 4.2 Million USD | -16.0% |
| 1999 Q2 | 5.2 Million USD | 23.81% |
| 1999 Q3 | 4.5 Million USD | -13.46% |
| 1999 Q4 | 5.3 Million USD | 17.78% |
| 1999 FY | 19.2 Million USD | 3.23% |
| 1998 Q2 | 2.7 Million USD | -18.18% |
| 1998 Q3 | 4.1 Million USD | 51.85% |
| 1998 Q4 | 5 Million USD | 21.95% |
| 1998 FY | 18.6 Million USD | 38.81% |
| 1998 Q1 | 3.3 Million USD | -40.0% |
| 1997 FY | 13.4 Million USD | 76.32% |
| 1997 Q2 | 2.4 Million USD | 20.0% |
| 1997 Q3 | 2.1 Million USD | -12.5% |
| 1997 Q4 | 5.5 Million USD | 161.9% |
| 1997 Q1 | 2 Million USD | 25.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | 7.6 Million USD | 0.0% |
| 1996 Q4 | 1.6 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -494.193% |
| Alpha Teknova, Inc. | 45.85 Million USD | -6.932% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 74.978% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -9.328% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 69.199% |
| Cosmos Health Inc. | 26.18 Million USD | -87.305% |
| Journey Medical Corporation | 54.59 Million USD | 10.177% |
| Embecta Corp. | 528.4 Million USD | 90.72% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 81.964% |
| Dynavax Technologies Corporation | 219.14 Million USD | 77.623% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 91.689% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 84.975% |
| PainReform Ltd. | 9.58 Million USD | -411.665% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -273.638% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -273.638% |
| SCYNEXIS, Inc. | 51.84 Million USD | 5.42% |
| Safety Shot Inc | 12.1 Million USD | -304.948% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1497.752% |
| Procaps Group, S.A. | 199.47 Million USD | 75.417% |
| Theratechnologies Inc. | 72.75 Million USD | 32.599% |
| Harrow Health, Inc. | 89.97 Million USD | 45.497% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -419.14% |
| Biofrontera Inc. | 39.95 Million USD | -22.721% |
| DURECT Corporation | 43.71 Million USD | -12.177% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 90.73% |
| Cronos Group Inc. | 96.7 Million USD | 49.293% |
| OptiNose, Inc. | 85.1 Million USD | 42.377% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 78.874% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -25.247% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 612.896% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 84.389% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -403.944% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -13.934% |
| Radius Health, Inc. | 265.92 Million USD | 81.56% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -254.272% |
| ProPhase Labs, Inc. | 37.85 Million USD | -29.552% |
| Phibro Animal Health Corporation | 260.29 Million USD | 81.161% |
| Procaps Group S.A. | 187.24 Million USD | 73.811% |
| Alvotech | 285.43 Million USD | 82.82% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -399.115% |
| Viatris Inc. | 5.96 Billion USD | 99.178% |
| Rockwell Medical, Inc. | 15.37 Million USD | -218.967% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 18.051% |
| SIGA Technologies, Inc. | 22.04 Million USD | -122.465% |
| Tilray Brands, Inc. | 251.35 Million USD | 80.491% |
| Shineco, Inc. | 17.94 Million USD | -173.222% |
| PetIQ, Inc. | 192.72 Million USD | 74.555% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1128.672% |
| Incannex Healthcare Limited | 30.05 Million USD | -63.172% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.928% |
| Alimera Sciences, Inc. | 62.64 Million USD | 21.716% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -6331.281% |
| Assertio Holdings, Inc. | 368.58 Million USD | 86.696% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -733.19% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -175.362% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -131.65% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -133.047% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 70.274% |
| Hempacco Co., Inc. | 7.59 Million USD | -545.538% |
| Talphera, Inc. | 11.99 Million USD | -308.854% |
| Alvotech | 285.43 Million USD | 82.82% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 65.151% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 85.782% |
| Currenc Group, Inc. | 24 Million USD | -104.307% |
| Kamada Ltd. | 45.42 Million USD | -7.951% |
| Indivior PLC | 911 Million USD | 94.617% |
| Evoke Pharma, Inc. | 12.4 Million USD | -295.16% |
| Flora Growth Corp. | 10.57 Million USD | -363.541% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -133.047% |
| Evolus, Inc. | 189.75 Million USD | 74.158% |
| HUTCHMED (China) Limited | 436.23 Million USD | 88.759% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 68.185% |
| Akanda Corp. | 3.48 Million USD | -1307.719% |